Creative Medical Technology Holdings, Inc.CELZ
What Creative Medical Technology Holdings, Inc. does.
We are a commercial stage biotechnology company dedicated to the advancement regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. Our platforms, therapies and products include the following:
Our subsidiary, Creative Medical Technologies, Inc. (“CMT”), was originally created to monetize U.S. Patent No. 8,372,797 and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired in February 2016. Subsequently, we have expanded our development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, Type-1 diabetes, and heart, liver, kidney, and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AlloCelz LLC subsidiaries. However, neither ImmCelz Inc., nor AlloCelz LLC have commenced commercial activities.
In 2020, through our ImmCelz Inc. subsidiary, we began developing treatments under our ImmCelz™ platform (CELZ-100), that utilize a patient’s own extracted immune cells that are then “reprogrammed/supercharged” by culturing them outside the patient’s body with optimized cell-free factors. The immune cells are then re-injected into the patient from whom they were extracted. We believe this process endows the immune cells with regenerative properties (or “supercharges” them) providing them with the ability to treat multiple indications. We have validated this ability through the third-party studies described below that were independently conducted on selected human donor patient cells for accuracy and reproducibility. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $164,500 | $87,754 | $88,600 | $9,000 | $11,000 | $6,000 |
| Net income | -$36.3M | $19.2M | -$10.1M | -$5.3M | -$5.5M | -$6.0M |
More on CELZ.
- Creative Medical Technology Holdings, Inc. summary
- Creative Medical Technology Holdings, Inc. financial statements
- Creative Medical Technology Holdings, Inc. key metrics
- Creative Medical Technology Holdings, Inc. health scores and style box
- Creative Medical Technology Holdings, Inc. earnings
- Creative Medical Technology Holdings, Inc. dividends
- Creative Medical Technology Holdings, Inc. valuation
- Creative Medical Technology Holdings, Inc. ownership and insiders
- Creative Medical Technology Holdings, Inc. peers
Figures from Creative Medical Technology Holdings, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.